Hyderabad: Indian pharmaceutical company Aurobindo Pharma Ltd is working on developing several other viral vaccines, including the coronavirus vaccine. For this, the company has also received approval from the Department of Biotechnology for funding. The company has given this information in its annual report.
At the moment, the company stated in its latest annual report that, 'During FY 2019-20, we have strengthened our presence in the vaccine segment by acquiring the R&D assets of Profactus Biosciences through Auro Vaccine. Many virus vaccines have been produced using these R&D assets, including the vaccine for Coronavirus. Arvindo Pharma has reported that in November 2019, its subsidiary Auro Vaccine LSC acquired a portion of Profactus Biosciences Inc. USA for Rs 80 crore.
The pharmaceutical company said in the annual report that, 'Biotechnology Industry Research Assistance Council, Department of Biotechnology (BIRAC) has evaluated our potential vaccine. BIRAC has extensively evaluated our platform and informed us that our vaccine has been selected for funding for initial development.